Brief: Positive Topline Clinical Results Support Streamlined Development Pathway For LPCN 1154
16/05/2023 12:10
May 16 (Reuters) - Lipocine Inc LPCN.O :
* POSITIVE TOPLINE CLINICAL RESULTS SUPPORT STREAMLINED
DEVELOPMENT PATHWAY FOR LPCN 1154, LIPOCINE'S ORAL CANDIDATE FOR
RAPID RELIEF OF DEPRESSION
* LIPOCINE INC - PLANS TO INITIATE CONFIRMATORY PIVOTAL PK
STUDY
IN 2H 2023
* LIPOCINE INC - LPCN 1154 TREATMENT WAS WELL-TOLERATED WITH
NO
HYPOXIA OR SEDATION-RELATED ADVERSE EVENTS
Source text for Eikon: ID:nPn3WG238a
Further company coverage: LPCN.O
Recent news on Lipocine
See all newsUS STOCKS ON THE MOVE-Halozyme, Moderna, Merck
U.S. STOCKS ON THE MOVE-Halozyme, BKV, AppFolio
U.S. STOCKS ON THE MOVE-Hecla Mining, XPO, Lipocine
Lipocine surges after Canada approves co's testosterone replacement therapy
Brief: Lipocine Announces Health Canada Approval Of Tlando For Testosterone Replacement Therapy